celecoxib has been researched along with tamoxifen in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (61.29) | 29.6817 |
| 2010's | 12 (38.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ali, HI; Ali, MM; El Diwani, HI; Ragab, FA; Shaker, YM; Temirak, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beitz, J | 1 |
| Gescher, AJ; O'Byrne, KJ; Sharma, RA; Steward, WP | 1 |
| Ellis, MJ | 1 |
| Kammerer, S | 1 |
| Zielinski, SL | 1 |
| Vanchieri, C | 1 |
| Goldman, G; Keidar, A; Klausner, JM; Rabau, M; Strul, H; Tulchinsky, H | 1 |
| Dai, ZJ; Kang, HF; Liu, XX; Wang, XJ; Xue, FJ; Xue, XH | 2 |
| Temple, WJ; Zippel, DB | 1 |
| Chen, S; Hu, D; Liu, X; Wang, Y | 1 |
| Gould, MN; Haag, JD; Lubet, RA; Mau, B; Woditschka, S | 1 |
| Gould, MN; Haag, JD; Sullivan, R; Woditschka, S | 1 |
| DiFrancesco, LM; Francis, WP; Kurien, E; Mack, LA; Schachar, NS; Temple, WJ; Zippel, D | 1 |
| Han, X; Lv, J; Shi, J; Sun, Y; Wang, S; Xia, W; Xu, S; Zhao, T | 1 |
| Glück, S | 1 |
| Lane, R | 1 |
| Das, S; Dey, KK; Kumar, BN; Mandal, M; Mazumdar, A; Parekh, A; Rajput, S | 1 |
| Ch Yiannakopoulou, E | 1 |
| El-Kashef, DH; El-Sheakh, AR | 1 |
4 review(s) available for celecoxib and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Familiar drugs may prevent cancer.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticarcinogenic Agents; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Folic Acid; Humans; Male; Neoplasms; Pyrazoles; Raloxifene Hydrochloride; Sulfonamides; Tamoxifen; Vitamin A | 2001 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; Drug Synergism; Female; Humans; Salicylates; Tamoxifen | 2015 |
27 other study(ies) available for celecoxib and tamoxifen
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Benzimidazoles; Drug Evaluation, Preclinical; Humans; Mass Spectrometry; MCF-7 Cells; Molecular Docking Simulation; Proton Magnetic Resonance Spectroscopy; Structure-Activity Relationship | 2014 |
Trial endpoints for drug approval in oncology: Chemoprevention.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Female; Humans; Intestinal Polyps; Investigational New Drug Application; Male; Pyrazoles; Sulfonamides; Tamoxifen; United States; United States Food and Drug Administration | 2001 |
Neoadjuvant endocrine therapy as a drug development strategy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Celecoxib; Clinical Trials as Topic; Drug Design; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Pyrazoles; Signal Transduction; Sulfonamides; Tamoxifen | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Celecoxib; Cell Transformation, Neoplastic; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Prescriptions; Female; Finasteride; Humans; Male; Neoplasms; Prostatic Neoplasms; Pyrazoles; Sulfonamides; Tamoxifen; United States | 2004 |
Vioxx withdrawal alarms cancer prevention researchers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Estrogen Receptor Modulators; Humans; Lactones; Neoplasms; Pyrazoles; Sulfonamides; Sulfones; Tamoxifen; United States; United States Food and Drug Administration | 2004 |
Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Celecoxib; Colectomy; Colorectal Neoplasms; Comorbidity; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Fibromatosis, Aggressive; Gardner Syndrome; Humans; Male; Middle Aged; Pyrazoles; Radiography; Retrospective Studies; Sulfonamides; Tamoxifen | 2005 |
[Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Drug Administration Routes; Drug Synergism; Female; Mammary Neoplasms, Experimental; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamoxifen | 2006 |
[Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Down-Regulation; Female; Immunohistochemistry; Mammary Neoplasms, Experimental; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamoxifen; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
When is a neoplasm not a neoplasm? When it is a desmoid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Celecoxib; Fibromatosis, Aggressive; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pyrazoles; Sulfonamides; Tamoxifen | 2007 |
Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis.
Topics: Acute Disease; Animals; Animals, Newborn; Celecoxib; Cell Hypoxia; Cell Survival; Cells, Cultured; Coronary Thrombosis; Cyclooxygenase 2 Inhibitors; Drugs, Chinese Herbal; Endothelial Cells; Estrogen Antagonists; Glyburide; Myocardial Ischemia; Myocytes, Cardiac; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamoxifen | 2007 |
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Topics: Animals; Anticarcinogenic Agents; Breast; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Pyrazoles; Rats; Rats, Inbred WF; Sulfonamides; Tamoxifen | 2008 |
A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Bexarotene; Carcinoma in Situ; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Pyrazoles; Rats; Rats, Inbred WF; Retroviridae; Sulfonamides; Tamoxifen; Tetrahydronaphthalenes; Time Factors | 2009 |
Desmoids: a revelation in biology and treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Doxorubicin; Female; Fibromatosis, Aggressive; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pyrazoles; Radiotherapy, Adjuvant; Soft Tissue Neoplasms; Sulfonamides; Tamoxifen; Young Adult | 2009 |
Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Female; Glycoproteins; Humans; Pyrazoles; Sulfonamides; Tamoxifen | 2009 |
A protocol for labrador retrievers?
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Hormonal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Doxycycline; Drug Combinations; Humans; Neoplasms; Pyrazoles; Smell; Sulfonamides; Tamoxifen | 2009 |
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Blotting, Western; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Neovascularization, Pathologic; Pyrazoles; Reactive Oxygen Species; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sulfonamides; Tamoxifen; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Hepatoprotective effect of celecoxib against tamoxifen-induced liver injury via inhibiting ASK-1/JNK pathway in female rats.
Topics: Animals; Antineoplastic Agents, Hormonal; Antioxidants; Celecoxib; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Liver; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 5; MAP Kinase Signaling System; Protective Factors; Rats; Rats, Sprague-Dawley; Tamoxifen | 2019 |